


[Development of Alzheimer's Disease Treatment]

<Current Treatments>

- Alzheimer's disease (AD) is a progressive neurodegenerative disorder caused primarily by the accumulation of amyloid- β (A β) in the brain.
- No cure to date. Existing treatments are limited to symptomatic therapy.


There is a need for new approaches to break down and remove amyloid- β (A β) accumulated in the brain.



<Research Goal>

To develop a cure for AD by using Catalytide which breaks down and removes A β .

Results to Date



Intranasal administration of AD-Cat degrades A β in the brain, suppresses inflammation and improves cognitive function. (Patent No. WO2017119511, Novel peptide exhibiting hydrolytic activity and use thereof)

R&D Plan

(1) Efficacy studies using genetically modified AD model mice


Evaluate efficacy in mouse models that closely mimic the human disease state. Based on acquisition of non-clinical proof of concept (POC) aimed at clinical trials, examine dosage and interval and determine method of administration and dosage.

(2) Non-clinical safety studies

Conduct acute toxicity studies at an external organisation compliant with Good Laboratory Practice (GLP) standards. Determine toxicity endpoints (immune response, organ toxicity).

Timeline

(1) Efficacy studies



(2) Non-clinical safety studies

